SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) just released its latest second-quarter results and things are looking bullish. Revenue crushed expectations at US$60m, beating expectations by 73%. SpringWorks Therapeutics reported a statutory loss of US$0.54 per share, which - although not amazing - was much smaller than the analysts predicted. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.

Check out our latest analysis for SpringWorks Therapeutics

Following the latest results, SpringWorks Therapeutics' eight analysts are now forecasting revenues of US$180.7m in 2024. This would be a huge 110% improvement in revenue compared to the last 12 months. Losses are forecast to narrow 3.9% to US$3.90 per share. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$145.1m and losses of US$4.58 per share in 2024. We can see there's definitely been a change in sentiment in this update, with the analysts administering a sizeable upgrade to this year's revenue estimates, while at the same time reducing their loss estimates.

Despite these upgrades,the analysts have not made any major changes to their price target of US$66.70, implying that their latest estimates don't have a long term impact on what they think the stock is worth. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on SpringWorks Therapeutics, with the most bullish analyst valuing it at US$80.00 and the most bearish at US$58.00 per share. Analysts definitely have varying views on the business, but the spread of estimates is not wide enough in our view to suggest that extreme outcomes could await SpringWorks Therapeutics shareholders.

One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. The analysts are definitely expecting SpringWorks Therapeutics' growth to accelerate, with the forecast 3x annualised growth to the end of 2024 ranking favourably alongside historical growth of 34% per annum over the past five years. Compare this with other companies in the same industry, which are forecast to grow their revenue 18% annually. It seems obvious that, while the growth outlook is brighter than the recent past, the analysts also expect SpringWorks Therapeutics to grow faster than the wider industry.